Ligands for BCMA include B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), and they act as growth and proliferation signals, attenuating cell death mechanism associated with NF-κB activation and playing as a survival factor, with maintenance and survival of malignant MM cells [10, 11]: this is probably why therapeutic strategies for blocking the BCMA pathway have proven to be so effective in MM. Here, NFKB1 is linked to Miyoshi myopathy.